Mobile website
Clinical Research
Clinical efficiency of radiotherapy combined with self-immune cell therapy for cervical carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To compare changes of cellular immune function and survival of cervical carcinoma patients receiving radiotherapy combined with self-immune cell therapy with those receiving radiotherapy alone. Methods: Sixty-eight cases of cervical carcinoma were divided into 2 groups: 38 cases in radiotherapy group; 30 cases in combination group (radiotherapy combined with self-immune cell therapy). Peripheral blood mononuclear cells (PBMCs) were separated, and then CD3AK cells, cytokine-induced killer cells (CIKs), dendritic cells (DCs), γδT cells and NK cells were induced and cultured. CD3+, CD4+, CD8+, CD19+, CD16+CD56+ and γδT cell numbers and ratios as well as the rate of positive expression of perforin, granzyme B (GraB), and CD107a of PBMCs were evaluated by FCM before and after treatment. The patients were followed by 5 years follow up study. Results: In most patients of the combination group, the quality of life was improved. The scores of Karnofsky in the combination group were significantly higher than those in the radiotherapy group (P<0.05). The immune cell numbers in the combination group were significantly higher than those in the radiotherapy group (P<005). The rates of the positive expression of perforin, GraB and CD107a of PBMCs were higher in the combination group than in the radiotherapy group correspondingly (P<0.05). The over-all 1-, 2- and 5-year survival rates of Ⅰb-Ⅳ stage patients were 93.3%(28/30), 83.3%(25/30) and 76.6%(23/30) in the combination group, and were 86.82%(33/38), 68.4%(26/38) and 57.9%(22/38) in the radiotherapy group, respectively (P<0.05) with Ⅱb and Ⅲ stage patients showing the most significance. Conclusion: Radiotherapy combined with self-immune cell therapy for cervical carcinoma can enhance the immune function and increase the survival.
Keywords:
Project Supported:
Project supported by the Medical Science and Technology Innovation Program of Nanjing Military Area Command（No.11MA040）
Clc Number:
